Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 4/2019

01-04-2019 | Breast Cancer | Letter to the Editor

Comment to Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease; an individual patient data analysis of three clinical trials

Authors: PD Dr. med. Christiane Matuschek, David Krug, Rainer J. Klement, René Baumann

Published in: Strahlentherapie und Onkologie | Issue 4/2019

Login to get access

Excerpt

Abdel-Rahman [1] analyzed the overall survival-rate and disease-free survival of T1-2 N1 breast cancer patients after mastectomy, who were adjuvantly treated with various modern chemotherapeutic drugs (anthracyclines, taxanes) in 3 prospective phase III chemotherapy trials. His analysis suggested no potential benefits of an additional adjuvant postmastectomy radiotherapy (PMRT). The included trials were the BIG 02/98 [6], the BCIRG 001 [7] and the BCIRG-005 [5] trials. The author concludes that in T1-2 N1 breast cancer patients who have received modern chemotherapy drugs PMRT does not provide any benefit for overall and disease-free survival. Prospective studies are necessary. …
Literature
1.
2.
Abdel-Rahman O, Cheung WY (2018) Impact of smoking history on the outcomes of women with early-stage breast cancer: a secondary analysis of a randomized study. Med Oncol 35:68CrossRefPubMed
3.
Budach W, Bolke E, Kammers K et al (2015) Adjuvant radiation therapy of regional lymph nodes in breast cancer—a meta-analysis of randomized trials- an update. Radiat Oncol 10:258CrossRefPubMedPubMedCentral
4.
Early Breast Cancer Trialists’ Collaborative Group, Mcgale P, Taylor C et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383:2127–2135CrossRef
5.
Eiermann W, Pienkowski T, Crown J et al (2011) Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2‑normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 29:3877–3884CrossRefPubMed
6.
Fernandez-Cuesta L, Oakman C, Falagan-Lotsch P et al (2012) Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res 14:R70CrossRefPubMedPubMedCentral
7.
Mackey JR, Martin M, Pienkowski T et al (2013) Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 14:72–80CrossRefPubMed
8.
Mcbride A, Allen P, Woodward W et al (2014) Locoregional recurrence risk for patients with T1,2 breast cancer with 1–3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys 89:392–398CrossRefPubMed
9.
Poortmans PM, Collette S, Kirkove C et al (2015) Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 373:317–327CrossRefPubMed
10.
Metadata
Title
Comment to Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease; an individual patient data analysis of three clinical trials
Authors
PD Dr. med. Christiane Matuschek
David Krug
Rainer J. Klement
René Baumann
Publication date
01-04-2019
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 4/2019
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-018-1411-2

Other articles of this Issue 4/2019

Strahlentherapie und Onkologie 4/2019 Go to the issue

Literatur kommentiert

Lokale Radiotherapie für Patienten mit einem neu diagnostizierten, metastasierten Prostatakarzinom

Original Article

Pattern of care of adjuvant radiotherapy in male breast cancer patients in clinical practice: an observational study

Editorial

Low-dose radiotherapy: Mayday, mayday. We’ve been hit!

Original Article

Comparison of treatment plans for a high-field MRI-linac and a conventional linac for esophageal cancer

Literatur kommentiert

Patienten mit metastatischer Rückenmarkskompression profitieren von rascher multidisziplinärer Diagnostik und Behandlung

Letter to the Editor

Reply to the letter to the editor “Comment to ‘Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease; an individual patient data analysis of three clinical trials’”